RIAD, Abanoub, Alshaimaa Ahmed SHABAAN, Julien ISSA, Sally IBRAHIM, Hatem AMER, Yossef MANSY, Islam KASSEM, Amira Bisher KASSEM, Hans-Peter HOWALDT, Miloslav KLUGAR a Sameh ATTIA. COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors. Journal of Fungi. Basel: MDPI, roč. 7, č. 10, s. 1-23. ISSN 2309-608X. doi:10.3390/jof7100837. 2021.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors
Autoři RIAD, Abanoub (818 Egypt, garant, domácí), Alshaimaa Ahmed SHABAAN, Julien ISSA, Sally IBRAHIM, Hatem AMER, Yossef MANSY, Islam KASSEM, Amira Bisher KASSEM, Hans-Peter HOWALDT, Miloslav KLUGAR (203 Česká republika, domácí) a Sameh ATTIA.
Vydání Journal of Fungi, Basel, MDPI, 2021, 2309-608X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 10612 Mycology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.724
Kód RIV RIV/00216224:14110/21:00122538
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/jof7100837
UT WoS 000715320700001
Klíčová slova anglicky co-infection; COVID-19; cross-infection; Mucorales; mucormycosis; mycoses; review; Rhizopus; risk factors; steroids
Štítky 14110525, 14119612, 14119613, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 7. 12. 2021 09:21.
Anotace
Background: Since the novel coronavirus disease (COVID-19) outbreak, the cases of COVID-19 co-infections have been increasingly reported worldwide. Mucormycosis, an opportunistic fungal infection caused by members of the Mucorales order, had been frequently isolated in severely and critically ill COVID-19 patients. Methods: Initially, the anamnestic, clinical, and paraclinical features of seven COVID-19-associated mucormycosis (CAM) cases from Egypt were thoroughly reported. Subsequently, an extensive review of the literature was carried out to describe the characteristics of CAM cases globally, aiming to explore the potential risk factors of mortality in CAM patients. Results: Out of the seven reported patients in the case series, five (71.4%) were males, six (85.7%) had diabetes mellitus, and three (42.9%) had cardiovascular disease. All patients exhibited various forms of facial deformities under the computed tomography scanning, and two of them tested positive for Mucorales using the polymerase chain reaction (PCR) testing. Liposomal amphotericin B (LAmB) was prescribed to all cases, and none of them died until the end of the follow-up. On reviewing the literature, 191 cases were reported worldwide, of which 74.4% were males, 83.2% were from low-middle income countries, and 51.4% were aged 55 years old or below. Diabetes mellitus (79.1%), chronic hypertension (30%), and renal disease/failure (13.6%) were the most common medical comorbidities, while steroids (64.5%) were the most frequently prescribed medication for COVID-19, followed by Remdesivir (18.2%), antibiotics (12.7%), and Tocilizumab (5.5%). Conclusions: As the majority of the included studies were observational studies, the obtained evidence needs to be interpreted carefully. Diabetes, steroids, and Remdesivir were not associated with increased mortality risk, thus confirming that steroids used to manage severe and critical COVID-19 patients should not be discontinued. Lung involvement, bilateral manifestation, and Rhizopus isolation were associated with increased mortality risk, thus confirming that proactive screening is imperative, especially for critically ill patients. Finally, surgical management and antimycotic medications, e.g., amphotericin B and posaconazole, were associated with decreased mortality risk, thus confirming their effectiveness.
Návaznosti
LTC20031, projekt VaVNázev: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST
MUNI/A/1608/2020, interní kód MUNázev: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
Investor: Masarykova univerzita, Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
MUNI/IGA/1543/2020, interní kód MUNázev: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Akronym: Evidence-Based Practice in Czechia)
Investor: Masarykova univerzita, Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic
VytisknoutZobrazeno: 29. 3. 2024 15:49